cas 1571-08-0|| where to buy Methyl 4-formylbenzoate

Nom du produit:Methyl 4-formylbenzoate

IUPAC Name:methyl 4-formylbenzoate

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM157703-1000g	in stock	ƿŤ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1571-08-0 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:1571-08-0; Formule moléculaire:C9H8O3; Point de fusion:-; Code SMILES:C1=C(C(OC)=O)C=CC(=C1)C=O; Densité:

: Numéro de catalogue:CM157703; Poids moléculaire:164.16; Point d'ébullition:265°C at 760 mmHg; N° Mdl:MFCD00006950; Stockage:Keep in Inert atmosphere, store at 2-8°C.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Risvodetinib; Inhibikase Therapeutics’s Risvodetinib (IkT-148009) has been granted Orphan Drug Designation by the U.S. FDA for the treatment of Multiple System Atrophy (MSA). MSA is a rapidly progressive rare condition of the nervous system that causes gradual damage to nerve cells in the brain, and shares many symptoms with Parkinson's disease. This neurological disorder has an estimate an average of 0.6 to 0.7 new cases per 100,000 people yearly.
The non-receptor tyrosine kinase Abelson, c-Abl is shown to be implicated in the initiation and progression of α-synuclein (α-syn) pathogenesis and neurodegeneration. Risvodetinib is a brain-penetrant selective inhibitor of c-Abl1 and Abl2 undergoing Phase 2 clinical studies.